|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
CN108137507A
(zh)
|
2015-07-10 |
2018-06-08 |
阿尔维纳斯股份有限公司 |
基于mdm2的蛋白水解调节剂和相关的使用方法
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
ES2975558T3
(es)
|
2016-09-15 |
2024-07-09 |
Arvinas Inc |
Derivados de indol como degradantes de receptor de estrógeno
|
|
AU2017348322B8
(en)
|
2016-10-28 |
2021-12-23 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating EZH2-mediated cancer
|
|
EP3535265A4
(en)
*
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
WO2018102725A1
(en)
|
2016-12-01 |
2018-06-07 |
Arvinas, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
|
|
EP3558994A4
(en)
|
2016-12-23 |
2021-05-12 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
|
|
RU2019121527A
(ru)
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
|
EP3577109A4
(en)
|
2017-01-31 |
2020-11-18 |
Arvinas Operations, Inc. |
CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
EP3641762B1
(en)
|
2017-06-20 |
2026-02-18 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
JP7258009B2
(ja)
|
2017-07-10 |
2023-04-14 |
セルジーン コーポレイション |
抗増殖化合物及びその使用方法
|
|
EP4310496A3
(en)
|
2017-07-12 |
2024-12-04 |
Dana-Farber Cancer Institute, Inc. |
Compounds for tau protein degradation
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
WO2019060693A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
KR20210018199A
(ko)
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
|
CN118754858A
(zh)
|
2018-03-26 |
2024-10-11 |
诺华股份有限公司 |
N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
KR20240130153A
(ko)
|
2018-04-01 |
2024-08-28 |
아비나스 오퍼레이션스, 인코포레이티드 |
Brm을 표적으로 하는 화합물 및 관련 사용 방법
|
|
CN119569702A
(zh)
|
2018-04-04 |
2025-03-07 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
EP3774772A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
FI3784663T3
(fi)
|
2018-04-23 |
2023-10-06 |
Celgene Corp |
Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
|
|
SG11202011135WA
(en)
|
2018-05-14 |
2020-12-30 |
Nuvation Bio Inc |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
AU2019294836B2
(en)
*
|
2018-06-29 |
2024-06-20 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
JP7328263B2
(ja)
|
2018-06-29 |
2023-08-16 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
免疫調節化合物
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CU20210002A7
(es)
|
2018-07-10 |
2021-08-06 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
CN112533898A
(zh)
|
2018-07-31 |
2021-03-19 |
日商泛美克斯股份有限公司 |
杂环化合物
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
AU2019323446B2
(en)
|
2018-08-22 |
2025-01-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
EP3846800A4
(en)
|
2018-09-04 |
2022-08-24 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
US11319330B2
(en)
*
|
2018-09-07 |
2022-05-03 |
Medshine Discovery Inc. |
Tricyclic furan-substituted piperidinedione compound
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
WO2020117759A1
(en)
*
|
2018-12-03 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Small molecule degraders of helios and methods of use
|
|
CN119219606A
(zh)
|
2018-12-19 |
2024-12-31 |
细胞基因公司 |
经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
|
|
BR112021012186A2
(pt)
*
|
2018-12-19 |
2021-08-31 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
CN120698983A
(zh)
*
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020160295A1
(en)
*
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
KR102876423B1
(ko)
*
|
2019-02-07 |
2025-10-24 |
한국화학연구원 |
표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
WO2020172655A1
(en)
*
|
2019-02-23 |
2020-08-27 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
|
WO2020206608A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
US12414995B2
(en)
|
2019-04-16 |
2025-09-16 |
Northwestern University |
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
|
|
KR20220004100A
(ko)
*
|
2019-04-18 |
2022-01-11 |
하이노바 파마슈티컬스 인코포레이티드 |
안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도
|
|
US12465648B2
(en)
|
2019-05-06 |
2025-11-11 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of HPK1
|
|
US11826430B2
(en)
|
2019-05-14 |
2023-11-28 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251969A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251971A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021011913A1
(en)
|
2019-07-17 |
2021-01-21 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
ES3061133T3
(en)
|
2019-08-26 |
2026-03-31 |
Arvinas Operations Inc |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
US20220388978A1
(en)
*
|
2019-08-27 |
2022-12-08 |
Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
|
CN114401962B
(zh)
*
|
2019-09-12 |
2024-05-24 |
南京明德新药研发有限公司 |
作为crbn蛋白调节剂的双并环类化合物
|
|
BR112022003514A2
(pt)
*
|
2019-09-16 |
2022-05-17 |
Novartis Ag |
Degradadores bifuncionais de brd9 e seus métodos de uso
|
|
EP4031243A1
(en)
*
|
2019-09-16 |
2022-07-27 |
Novartis AG |
Glue degraders and methods of use thereof
|
|
WO2021067606A1
(en)
|
2019-10-01 |
2021-04-08 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
US12310975B2
(en)
|
2019-10-17 |
2025-05-27 |
Arvinas Operations, Inc. |
Modulators of BCL6 proteolysis and associated methods of use
|
|
US11952349B2
(en)
|
2019-11-13 |
2024-04-09 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
EP4072591A4
(en)
|
2019-12-10 |
2024-06-05 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADER AND USES THEREOF
|
|
GB201918414D0
(en)
*
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP2023509366A
(ja)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
EP4076001A4
(en)
*
|
2019-12-17 |
2023-12-20 |
Orionis Biosciences, Inc. |
MODULATION OF PROTEIN DEGRADATION
|
|
EP4077309A1
(en)
*
|
2019-12-19 |
2022-10-26 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
US12569485B2
(en)
|
2019-12-23 |
2026-03-10 |
Kymera Therapeutics, Inc. |
SMARCA inhibitors and uses thereof
|
|
EP4083020A4
(en)
|
2019-12-23 |
2024-01-24 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
PREPARATION METHOD AND APPLICATION OF PROTEIN DEGRADATION AGENT COMPOUND
|
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
|
CA3164578A1
(en)
*
|
2020-01-14 |
2021-07-22 |
Scott KANNER |
Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
|
|
WO2021143816A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
WO2021143822A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
并环酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
US12528814B2
(en)
|
2020-02-19 |
2026-01-20 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
JP7692924B2
(ja)
|
2020-02-26 |
2025-06-16 |
クルゲン（シャンハイ），インク． |
トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
IL295709A
(en)
|
2020-03-05 |
2022-10-01 |
C4 Therapeutics Inc |
Compounds for targeted degradation of brd9
|
|
AU2021229979A1
(en)
*
|
2020-03-06 |
2022-10-27 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound acting on CRBN protein and preparation method therefor
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
JP2023518202A
(ja)
*
|
2020-03-18 |
2023-04-28 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｐｅｔトレーサーｐｂｂ３に基づく異常タウの標的化ディグレーダー
|
|
IL296451B2
(en)
|
2020-03-19 |
2026-05-01 |
Kymera Therapeutics Inc |
MDM2 joints and their uses
|
|
KR20210122164A
(ko)
*
|
2020-03-27 |
2021-10-08 |
(주) 업테라 |
Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
WO2021219077A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
US20230357249A1
(en)
*
|
2020-05-14 |
2023-11-09 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
CA3172589A1
(en)
*
|
2020-05-21 |
2021-11-25 |
Dana-Farber Cancer Institute, Inc. |
Piperidine-2,6-diones as small molecule degraders of helios and methods of use
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4166550A4
(en)
|
2020-06-12 |
2024-08-07 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
PHTHALAZINONE COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
|
|
CA3173629A1
(en)
|
2020-06-19 |
2021-12-13 |
Cosimo Dolente |
Braf degraders
|
|
CA3178172A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Eric Fischer |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
CN115697992B
(zh)
*
|
2020-07-09 |
2025-09-19 |
西藏海思科制药有限公司 |
一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
|
|
EP4186904A4
(en)
*
|
2020-07-21 |
2024-09-04 |
Ubix Therapeutics, Inc. |
COMPOUND FOR DEGRADING THE ANDROGEN RECEPTOR AND PHARMACEUTICAL USE THEREOF
|
|
KR20220014952A
(ko)
*
|
2020-07-29 |
2022-02-08 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
CN116457344B
(zh)
*
|
2020-08-03 |
2026-05-12 |
凯普托尔治疗学股份有限公司 |
低分子量蛋白质降解剂及其应用
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
JP7591301B2
(ja)
*
|
2020-08-05 |
2024-11-28 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
タンパク質を標的とし、分解するための化合物ならびにその調製方法および使用
|
|
EP4204418A1
(en)
|
2020-08-28 |
2023-07-05 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CN116209439A
(zh)
|
2020-09-23 |
2023-06-02 |
圣裘德儿童研究医院有限公司 |
作为cereblon蛋白调节剂的取代的N-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)芳基磺酰胺类似物
|
|
EP4221756A1
(en)
*
|
2020-09-30 |
2023-08-09 |
Astrazeneca AB |
Compounds and their use in treating cancer
|
|
KR20230107807A
(ko)
*
|
2020-10-14 |
2023-07-18 |
씨4 테라퓨틱스, 인코포레이티드 |
의료 요법을 위한 신생기질을 분해하는 트리시클릭 화합물
|
|
MX2023004545A
(es)
|
2020-10-21 |
2023-07-05 |
Arvinas Operations Inc |
Compuestos y métodos para la degradación dirigida de la proteína del receptor de andrógenos.
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
WO2022147465A1
(en)
|
2020-12-30 |
2022-07-07 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
EP4289841A4
(en)
*
|
2021-02-04 |
2025-02-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Benzo seven-membered ring bifunctional compound and application thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
WO2022178532A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US20250276964A1
(en)
*
|
2021-03-15 |
2025-09-04 |
Novartis Ag |
Benzisoxazole Derivatives and Uses thereof
|
|
CN116940571A
(zh)
*
|
2021-03-15 |
2023-10-24 |
诺华股份有限公司 |
苯并异噁唑衍生物及其用途
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
BR112023019967A2
(pt)
|
2021-03-29 |
2023-11-14 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
US20240217968A1
(en)
*
|
2021-03-31 |
2024-07-04 |
Duke Street Bio Limited |
Pharmaceutical compound
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
CA3214806A1
(en)
|
2021-04-16 |
2022-10-20 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
US12006314B2
(en)
*
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
BR112023023065A2
(pt)
|
2021-05-05 |
2024-01-30 |
Biogen Ma Inc |
Compostos para direcionar a degradação da tirosina quinase de bruton
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
JP2024519628A
(ja)
*
|
2021-05-26 |
2024-05-21 |
イノキュア セラピューティクス インコーポレイテッド |
ピペリジンジオン誘導体
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
JP2024523839A
(ja)
|
2021-06-08 |
2024-07-02 |
シーフォー セラピューティクス， インコーポレイテッド |
突然変異体ｂｒａｆを分解する療法薬
|
|
JP2024526192A
(ja)
*
|
2021-06-25 |
2024-07-17 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
WO2022272061A1
(en)
*
|
2021-06-25 |
2022-12-29 |
Celgene Corporation |
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
|
|
WO2022272074A1
(en)
*
|
2021-06-25 |
2022-12-29 |
Celgene Corporation |
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
KR20240035526A
(ko)
|
2021-07-07 |
2024-03-15 |
바이오젠 엠에이 인코포레이티드 |
Irak4 단백질의 분해를 표적하는 화합물
|
|
JP2024525580A
(ja)
|
2021-07-07 |
2024-07-12 |
バイオジェン・エムエイ・インコーポレイテッド |
Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
|
|
MX2024000313A
(es)
|
2021-07-09 |
2024-03-06 |
Plexium Inc |
Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.
|
|
KR102604801B1
(ko)
*
|
2021-08-10 |
2023-11-22 |
(주) 업테라 |
신규 plk1 분해 유도 화합물
|
|
WO2023016518A1
(zh)
*
|
2021-08-11 |
2023-02-16 |
四川海思科制药有限公司 |
一种杂环衍生物及其组合物和药学上的应用
|
|
EP4367118B1
(en)
|
2021-08-18 |
2025-01-29 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
US20240368194A1
(en)
*
|
2021-08-23 |
2024-11-07 |
Shanghai Leadingtac Pharmaceutical Co. Ltd. |
Irak4 degradation agent, and preparation method therefor and use thereof
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
US20240409528A1
(en)
*
|
2021-10-01 |
2024-12-12 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
WO2023059792A1
(en)
*
|
2021-10-06 |
2023-04-13 |
C4 Thrapeutics, Inc. |
Coronavirus non-structural protein 3 degrading compounds
|
|
KR20240110576A
(ko)
*
|
2021-10-22 |
2024-07-15 |
글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. |
Crbn e3 리가제 리간드 화합물, 리간드 화합물에 기초하여 개발된 단백질 분해제 및 이들의 응용
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
AU2022376954B2
(en)
|
2021-10-29 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
US20250122166A1
(en)
*
|
2021-11-03 |
2025-04-17 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
WO2023081452A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
EP4434992A4
(en)
*
|
2021-11-18 |
2026-02-11 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
FUSIONIZED IMIDE DERIVATIVE
|
|
CN118679160A
(zh)
|
2021-11-24 |
2024-09-20 |
阿维纳斯运营公司 |
Brm靶向化合物和相关的使用方法
|
|
US20250064945A1
(en)
|
2021-11-24 |
2025-02-27 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
CN118234726A
(zh)
|
2021-11-25 |
2024-06-21 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2022419982B2
(en)
|
2021-12-22 |
2026-04-16 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
IL314437A
(en)
|
2022-01-31 |
2024-09-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN119301111A
(zh)
*
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|
|
KR20250028370A
(ko)
*
|
2022-06-30 |
2025-02-28 |
안혼 메디신즈 컴퍼니, 리미티드 |
이작용성 화합물 및 이작용성 화합물을 포함하는 약제학적 조성물, 및 이를 사용하여 안드로겐 수용체 관련 질환을 치료하기 위한 방법
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024015412A1
(en)
*
|
2022-07-12 |
2024-01-18 |
Regents Of The University Of Michigan |
Tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
EP4585592A1
(en)
*
|
2022-09-08 |
2025-07-16 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Molecular glue compound based on cereblon protein design and use thereof
|
|
WO2024054953A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
US20250388575A1
(en)
*
|
2022-09-08 |
2025-12-25 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
JP2025531869A
(ja)
|
2022-09-09 |
2025-09-25 |
イノヴォ セラピューティクス、インコーポレイテッド |
ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
|
|
US20260098043A1
(en)
*
|
2022-09-14 |
2026-04-09 |
Hainan Simcere Zaiming Pharmeceutical Co., Ltd. |
Polycyclic compound and use thereof
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
CN119998300A
(zh)
*
|
2022-09-29 |
2025-05-13 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN120035586A
(zh)
*
|
2022-09-29 |
2025-05-23 |
江苏恒瑞医药股份有限公司 |
一种四氢萘类衍生物的可药用盐、晶型及制备方法
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
US20240180900A1
(en)
|
2022-10-24 |
2024-06-06 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
WO2024112122A1
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
KR20240076745A
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
JP2025538556A
(ja)
*
|
2022-11-22 |
2025-11-28 |
イノキュア セラピューティクス，インコーポレイテッド |
Ｃｍｅｔタンパク質を分解するための分解剤、およびそれを含む薬学的組成物
|
|
EP4630414A1
(en)
*
|
2022-12-06 |
2025-10-15 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
CN120225509A
(zh)
|
2022-12-22 |
2025-06-27 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2024153025A1
(zh)
*
|
2023-01-16 |
2024-07-25 |
南京明德新药研发有限公司 |
取代的苯并七元环化合物及其应用
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
CN120677148A
(zh)
*
|
2023-02-16 |
2025-09-19 |
百时美施贵宝公司 |
作为ret激酶降解剂的异吲哚啉酮戊二酰亚胺和苯基戊二酰亚胺类似物
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
TW202508568A
(zh)
|
2023-04-07 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
Ｉｒａｋ４蛋白水解靶向嵌合體
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024256729A1
(en)
*
|
2023-04-20 |
2025-09-25 |
Auron Therapeutics, Inc. |
Technologies targeting cell states
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
EP4720059A1
(en)
|
2023-05-24 |
2026-04-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024245444A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
标新生物医药科技(上海)有限公司 |
氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
|
|
EP4722206A1
(en)
*
|
2023-06-01 |
2026-04-08 |
Haihe Biopharma Co., Ltd. |
Benzo(hetero)cycloalkyl compounds for androgen receptor-dependent diseases
|
|
CN120202200A
(zh)
*
|
2023-06-01 |
2025-06-24 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
AU2024305423A1
(en)
|
2023-06-14 |
2026-01-22 |
Astrazeneca Ab |
Smarca2 degraders and uses thereof
|
|
UY40785A
(es)
|
2023-06-14 |
2024-12-31 |
Astrazeneca Ab |
Degradadores de smarca2 y usos de los mismos antecedentes
|
|
CN121969608A
(zh)
*
|
2023-06-23 |
2026-05-01 |
匹兹堡大学联邦系统高等教育 |
用于治疗HIV疾病的HIV-1 Nef靶向降解剂
|
|
AU2024310341A1
(en)
|
2023-06-30 |
2026-02-12 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
EP4735438A2
(en)
|
2023-06-30 |
2026-05-06 |
Merck Patent GmbH |
Heterobifunctional compounds for the degradation of kras
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
CN121773112A
(zh)
|
2023-08-17 |
2026-03-31 |
海思科医药集团股份有限公司 |
一种氰基芳香环衍生物及其在医药上的应用
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN119613374A
(zh)
*
|
2023-09-14 |
2025-03-14 |
中国科学院上海药物研究所 |
吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
AU2024344247A1
(en)
|
2023-09-19 |
2026-05-07 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
IL326555A
(en)
*
|
2023-09-22 |
2026-04-01 |
Glaxosmithkline Ip Dev Ltd |
Androgen receptor protax
|
|
WO2025070690A1
(ja)
|
2023-09-29 |
2025-04-03 |
第一三共株式会社 |
３－フェニルプロピルアミン誘導体
|
|
WO2025075693A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Purdue Research Foundation |
Shp2 degraders for cancer therapy
|
|
TW202523291A
(zh)
|
2023-11-02 |
2025-06-16 |
美商金橘生物科技公司 |
降解劑及其用途
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025114875A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025188857A1
(en)
*
|
2024-03-05 |
2025-09-12 |
University Of Florida Research Foundation, Incorporated |
Hdac8 degraders and uses thereof
|
|
US12558428B2
(en)
|
2024-03-08 |
2026-02-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TW202606657A
(zh)
*
|
2024-06-27 |
2026-02-16 |
南韓商韓美藥品股份有限公司 |
新型異雙功能蛋白質降解劑以及包含其的藥物組成物
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN119241498B
(zh)
*
|
2024-09-26 |
2026-04-07 |
天津科技大学 |
一种具有抗mash活性的acly靶向protac嵌合体、方法和应用
|
|
WO2026089992A1
(en)
|
2024-10-21 |
2026-04-30 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|